Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C.

Sci Transl Med. 2017 Nov 1;9(414). pii: eaao1690. doi: 10.1126/scitranslmed.aao1690.

PMID:
29093181
2.

Attacking cancer at its foundation.

Lydon N.

Nat Med. 2009 Oct;15(10):1153-7. doi: 10.1038/nm1009-1153. No abstract available.

PMID:
19812577
3.

Lessons learned from the development of imatinib.

Lydon NB, Druker BJ.

Leuk Res. 2004 May;28 Suppl 1:S29-38. Review. No abstract available.

PMID:
15036939
4.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL.

N Engl J Med. 2001 Apr 5;344(14):1031-7.

5.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.

J Pharmacol Exp Ther. 2000 Oct;295(1):139-45.

PMID:
10991971
6.

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Druker BJ, Lydon NB.

J Clin Invest. 2000 Jan;105(1):3-7. Review. No abstract available.

7.

The structure-based design of ATP-site directed protein kinase inhibitors.

Toledo LM, Lydon NB, Elbaum D.

Curr Med Chem. 1999 Sep;6(9):775-805. Review.

PMID:
10495352
8.

Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src.

Shen Z, Batzer A, Koehler JA, Polakis P, Schlessinger J, Lydon NB, Moran MF.

Oncogene. 1999 Aug 19;18(33):4647-53.

9.

Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis.

Stover DR, Lydon NB, Nunes JJ.

Curr Opin Drug Discov Devel. 1999 Jul;2(4):274-85.

PMID:
19649955
10.

Author errata.

Lydon N, Mett H, Mueller M, Becker M, Cozens RM, Daniels D, Traxler P, Buchdunger E, Stover D.

Int J Cancer. 1999 May 17;81(4):669. No abstract available.

11.

Retractions.

Buchdunger E, Trinks U, Mett H, Regenass U, Meyer T, McGlynn E, Pinna LA, Traxler P, Lydon NB, Zimmermann J.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12069. No abstract available.

12.

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H.

Clin Cancer Res. 1998 Jul;4(7):1661-72.

13.
15.

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB.

Blood Cells Mol Dis. 1997 Dec;23(3):380-94.

PMID:
9446752
16.
17.

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ.

Blood. 1997 Dec 15;90(12):4947-52.

PMID:
9389713
18.

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P.

J Med Chem. 1997 Oct 24;40(22):3601-16.

PMID:
9357527
19.

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

Deininger MW, Goldman JM, Lydon N, Melo JV.

Blood. 1997 Nov 1;90(9):3691-8.

PMID:
9345054
20.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.

J Pharm Belg. 1997 Mar-Apr;52(2):88-96. Review.

PMID:
9193132
21.

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).

Zimmermann J, Caravatti G, Mett H, Meyer T, Müller M, Lydon NB, Fabbro D.

Arch Pharm (Weinheim). 1996 Jul;329(7):371-6.

PMID:
8764886
22.

A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors.

Corbley MJ, Cherington V, Traxler PM, Lydon NB, Roberts TM.

Int J Cancer. 1996 Jun 11;66(6):753-9.

23.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.

J Med Chem. 1996 Jun 7;39(12):2285-92.

PMID:
8691423
24.
25.

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB.

Nat Med. 1996 May;2(5):561-6.

PMID:
8616716
26.

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB.

Cancer Res. 1996 Jan 1;56(1):100-4.

27.

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411.

Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U, Traxler P.

J Comput Aided Mol Des. 1995 Dec;9(6):465-72.

PMID:
8789188
28.
29.

[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.

Traxler P, Trinks U, Buchdunger E, Mett H, Meyer T, Müller M, Regenass U, Rösel J, Lydon N.

J Med Chem. 1995 Jun 23;38(13):2441-8.

PMID:
7608909
31.
32.

Cdc2-mediated modulation of pp60c-src activity.

Stover DR, Liebetanz J, Lydon NB.

J Biol Chem. 1994 Oct 28;269(43):26885-9.

33.

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.

Trinks U, Buchdunger E, Furet P, Kump W, Mett H, Meyer T, Müller M, Regenass U, Rihs G, Lydon N, et al.

J Med Chem. 1994 Apr 1;37(7):1015-27.

PMID:
8151612
35.

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, et al.

Cancer Res. 1994 Jan 1;54(1):16-20.

36.

Cellular and in vivo characterization of the MCR rat mammary tumor model.

Gutzwiller A, Regenass U, Matter A, Lydon NB.

Int J Cancer. 1993 Feb 1;53(3):486-92.

PMID:
7679091
37.

Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase.

Lydon NB, Gay B, Mett H, Murray B, Liebetanz J, Gutzwiller A, Piwnica-Worms H, Roberts TM, McGlynn E.

Biochem J. 1992 Nov 1;287 ( Pt 3):985-93.

38.

Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.

Geissler JF, Roesel JL, Meyer T, Trinks UP, Traxler P, Lydon NB.

Cancer Res. 1992 Aug 15;52(16):4492-8.

39.

Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus.

McGlynn E, Liebetanz J, Reutener S, Wood J, Lydon NB, Hofstetter H, Vanek M, Meyer T, Fabbro D.

J Cell Biochem. 1992 Jul;49(3):239-50.

PMID:
1644861
40.
41.

Hepatitis B virus polymerase gene: expression of the long open reading frame using the baculovirus expression system.

McGlynn E, Reutener S, Matter A, Wildner G, Will H, Lydon NB.

J Gen Virol. 1992 Jun;73 ( Pt 6):1515-9.

PMID:
1607871
42.
43.

The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase.

Bottari SP, King IN, Reichlin S, Dahlstroem I, Lydon N, de Gasparo M.

Biochem Biophys Res Commun. 1992 Feb 28;183(1):206-11.

PMID:
1347447
44.

Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

Traxler PM, Wacker O, Bach HL, Geissler JF, Kump W, Meyer T, Regenass U, Roesel JL, Lydon N.

J Med Chem. 1991 Aug;34(8):2328-37.

PMID:
1652014
45.

Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

Geissler JF, Traxler P, Regenass U, Murray BJ, Roesel JL, Meyer T, McGlynn E, Storni A, Lydon NB.

J Biol Chem. 1990 Dec 25;265(36):22255-61.

46.

An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase.

Lydon NB, Adams B, Poschet JF, Gutzwiller A, Matter A.

Oncogene Res. 1990;5(3):161-73.

PMID:
2157186
47.

Electroporation of cultured adult rat hepatocytes with the c-myc gene potentiates DNA synthesis in response to epidermal growth factor.

Muakkassah-Kelly SF, Jans DA, Lydon N, Bieri F, Waechter F, Bentley P, Stäubli W.

Exp Cell Res. 1988 Oct;178(2):296-306.

PMID:
3049121
48.

Immunochemical mapping of alpha-2 interferon.

Lydon NB, Favre C, Bove S, Neyret O, Benureau S, Levine AM, Seelig GF, Nagabhushan TL, Trotta PP.

Biochemistry. 1985 Jul 16;24(15):4131-41.

PMID:
2413884
49.
50.

Supplemental Content

Support Center